carboplatin + tamoxifen

Carboplatin + tamoxifen is a combination therapy consisting of two distinct drugs used primarily in oncology. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to apoptosis in rapidly dividing tumor cells. Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as an antagonist of the estrogen receptor in breast tissue, inhibiting the proliferative action of estrogen on mammary epithelium. This combination has been investigated for synergistic effects, particularly in high-grade gliomas and antiestrogen-resistant breast cancer, where it may improve survival outcomes compared to monotherapy or other regimens[1][3]. The rationale for combining these agents lies in their complementary mechanisms—carboplatin’s cytotoxicity and tamoxifen’s hormonal modulation—which together may enhance antitumor efficacy.